Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 221-234 , June 2006

Treatment of hirsutism and acne in hyperandrogenism

  • Paolo Moghetti, MD, PhD (Associate Professor of Endocrinology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39 045 8073110; Fax: +39 045 917374.

References 

  1. Balfour JA, McClellan K. Topical eflornithine. American Journal of Clinical Dermatology. 2001;2:197–201
  2. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocrine Reviews. 2000;21:347–362
  3. Harper JC. Hormonal therapy for acne using oral contraceptive pills. Seminars in Cutaneous Medicine and Surgery. 2005;24:103–106
  4. Lucky A, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls. Archives of Dermatology. 1994;130:308–314
  5. Choudhry R, Hodgins M, Van der Kwast T, et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. The Journal of Endocrinology. 1991;133:467–475
  6. Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production: studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. The Journal of Clinical Endocrinology and Metabolism. 1993;76:524–528
  7. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. The Journal of Clinical Endocrinology and Metabolism. 2004;89:453–462
  8. Arowojolu AO, Gallo MF, Grimes DA, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews. 2004;CD004425
  9. Stewart ME, Greenwood R, Cunliffe WJ, et al. Effect of cyproterone acetate-ethinyl oestradiol treatment on the proportion of linoleic and sebaceous acids in various skin surface lipid classes. Archives of Dermatological Research. 1986;278:481–485
  10. Baille A, Calman K, Milne J. Histochemical distribution of hydroxysteroid dehydrogenases in human skin. The British Journal of Dermatology. 1965;7:610–616
  11. Toscano V, Balducci R, Bianchi P, et al. Two different pathogenetic mechanisms may play a role in acne and in hirsutism. Clinical Endocrinology. 1993;39:551–556
  12. Azziz R. The evaluation and management of hirsutism. Obstetrics and Gynecology. 2003;101:995–1007
  13. Barth JH. How robust is the methodology for trials of therapy in hirsute women?. Clinical Endocrinology. 1996;45:379–380
  14. Azziz R, Ochoa TM, Bradley EL, et al. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. The Journal of Clinical Endocrinology and Metabolism. 1995;80:3406–3411
  15. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective, randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate–estrogen regimens in the treatment of hirsutism. The Journal of Clinical Endocrinology and Metabolism. 1999;84:1304–1310
  16. Moghetti P. Insulin resistance: what is its role in PCOS?. Current Opinion in Endocrinology Diabetes. 2002;9:444–450
  17. Gambineri A, Patton L, De Iasio R, et al. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3854–3862
  18. Richards RN. Electrolysis for the treatment of hypertrichosis and hirsutism. Skin Therapy Letter. 1999;4:3–4
  19. Sanchez LA, Perez M, Azziz R. Laser hair reduction in the hirsute patient: a critical assessment. Human Reproduction Update. 2002;8:169–181
  20. Clayton WJ, Lipton M, Elford J, et al. A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome. The British Journal of Dermatology. 2005;152:986–992
  21. Kopera D. Hair reduction: 48 months of experience with 800 nm diode laser. Journal of Cosmetic and Laser Therapy. 2003;5:146–149
  22. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2817–2823
  23. Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. The Journal of Family Planning and Reproductive Health Care. 2004;30:163–165
  24. Ibanez L, de Zegher F. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Human Reproduction (Oxford, England). 2004;19:1725–1727
  25. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane database of Systematic Reviews. 2003;CD001125
  26. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clinical Endocrinology. 1991;35:5–10
  27. McMullen GR, Van Herle AJ. Hirsutism and the effectiveness of spironolactone in its management. Journal of Endocrinological Investigation. 1993;16:925–932
  28. Lee O, Farquhar C, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane database of Systematic Reviews. 2000;CD000194
  29. Lobo RA, Shoupe D, Serafini P, et al. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertility and Sterility. 1985;43:200–205
  30. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism: a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2000;85:89–94
  31. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2756–2762
  32. Simard J, Luthy I, Guay J, et al. Characteristics of interaction of the anti-androgen flutamide with the androgen receptor in various target tissues. Molecular and Cellular Endocrinology. 1986;44:261–270
  33. Cusan L, Dupont A, Belanger A, et al. Treatment of hirsutism with the pure anti-androgen flutamide. Journal of the American Academy of Dermatology. 1990;23:462–469
  34. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clinical Endocrinology. 2004;60:241–249
  35. Diamanti-Kandarakis E, Mitrakou A, Raptis S, et al. The effect of a pure anti-androgen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2699–2705
  36. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and nonfatal hepatotoxicity associated with flutamide. Annals of Internal Medicine. 1993;118:860–864
  37. Kelestimur F, Everest H, Unluhizarci K, et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. European Journal of Endocrinology. 2004;150:351–354
  38. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2003;CD003053
  39. Harborne L, Fleming R, Lyall H, et al. Metformin or anti-androgen in the treatment of hirsutism in polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2003;88:4116–4123
  40. Azziz R, Ehrmann D, Legro RS, et al. PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1626–1632
  41. Gollnick H. Current concepts of the pathogenesis of acne. Drugs. 2003;63:1579–1596
  42. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67:4–9
  43. Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1%. Cutis. 2001;67:10–16
  44. Shalita A, Weiss JS, Chalker DK, et al. Comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. Journal of the American Academy of Dermatology. 1996;34:482–485
  45. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. Journal of the American Academy of Dermatology. 1998;38:S17–S23
  46. Thiboutot D. New treatments and therapeutic strategies for acne. Archives of Family Medicine. 2000;9:179–187
  47. White GM. Acne therapy. Disease-a-month: DM. 1999;45:301–330
  48. Nguyen QH, Kim YA, Schwartz RA. Management of acne vulgaris. American Family Physician. 1994;50:89–100
  49. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Archives of Dermatology. 1994;130:748–752
  50. Hubbell CG, Hobbs ER, Rist T, White JW. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Archives of Dermatology. 1982;118:989–992
  51. Garner SE, Eady EA, Popescu C, et al. Minocycline for Acne vulgaris: efficacy and safety. Cochrane Database of Systematic Reviews. 2000;CD002086
  52. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. The British Journal of Dermatology. 1989;121:51–57
  53. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. The Medical Journal of Australia. 1998;169:259–261
  54. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Archives of Dermatology. 1998;134:376
  55. Hurwitz S. Acne vulgaris: its pathogenesis and management. Adolescent Medicine (Philadelphia, Pa. ). 1990;1:301–314

PII: S1521-690X(06)00025-X

doi: 10.1016/j.beem.2006.03.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 221-234 , June 2006

Article Tools